Delaying Pediatric Type 1 Diabetes: Latest Research & Clinical Insights
Mayo Clinic researchers have demonstrated that a novel immunotherapy regimen can delay the onset of type 1 diabetes (T1D) in high-risk pediatric patients by an average of 3.5 years, according ... Read More